Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

109
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
109
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

45
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
45
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

331
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
331
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

103
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
103
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

36
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
36
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

456
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
456

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patients' perspectives of eosinophilic granulomatosis with polyangiitis within the context of a clinical trial.

EULAR rheumatology open·2026
Same author

Patient perspectives on glucocorticoid-associated complications and sequelae in ANCA-associated vasculitis.

EULAR rheumatology open·2026
Same author

EGPAware: a European Delphi consensus study on red flags for suspicion of eosinophilic granulomatosis with polyangiitis.

EULAR rheumatology open·2026
Same author

Yield and predictors of conversion on serial amyloid nuclear SPECT/CT in at-risk populations for transthyretin cardiac amyloidosis.

European heart journal. Imaging methods and practice·2026
Same author

Comparative habitat-associated patterns of pathomorphological changes in the internal organs of the European brown hare (<i>Lepus europaeus Pall</i>.).

Veterinary world·2026
Same author

Treatment strategies in giant cell arteritis and polymyalgia rheumatica: beyond glucocorticoids.

Nature reviews. Rheumatology·2026

Related Experiment Video

Updated: May 16, 2025

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

2.8K

[Lupus nephritis - does a lot help a lot?]

Cornelia Elisabeth Eckert, Bruno Reible, Zoran Popovic

    Deutsche Medizinische Wochenschrift (1946)
    |March 31, 2025
    PubMed
    Summary

    Lupus nephritis (LN) treatment has improved with targeted immunomodulating therapies. Combination therapies, including calcineurin inhibitors or belimumab, show superior renal outcomes compared to single agents.

    More Related Videos

    5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
    08:50

    5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

    Published on: July 3, 2013

    23.5K
    Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
    07:13

    Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

    Published on: April 12, 2021

    4.2K

    Related Experiment Videos

    Last Updated: May 16, 2025

    Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
    09:43

    Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

    Published on: June 8, 2022

    2.8K
    5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
    08:50

    5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

    Published on: July 3, 2013

    23.5K
    Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
    07:13

    Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

    Published on: April 12, 2021

    4.2K

    Area of Science:

    • Nephrology
    • Immunology
    • Rheumatology

    Background:

    • Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus, often leading to kidney failure.
    • Early diagnosis and treatment are critical for preserving kidney function.

    Purpose of the Study:

    • To review current advancements in lupus nephritis treatment.
    • To highlight the efficacy of combination immunomodulatory therapies.

    Main Methods:

    • Review of recent study data on lupus nephritis treatment strategies.
    • Analysis of clinical trial outcomes for various immunomodulatory agents.

    Main Results:

    • Combination therapies (e.g., calcineurin inhibitors, belimumab) demonstrate superior renal endpoints compared to monotherapy.
    • Multi-target therapy is now recommended in updated international guidelines.
    • CAR-T cell therapy shows future promise for refractory cases.

    Conclusions:

    • Current treatment approaches significantly improve renal prognosis in lupus nephritis.
    • Combination immunomodulatory therapy represents a key advancement in managing LN.
    • Future research into novel therapies like CAR-T cell therapy is warranted.